{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:13:53Z","timestamp":1794597233726,"version":"4.9.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.neuropharm.2022.109262","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:45:05Z","timestamp":1663847105000},"page":"109262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1126","authenticated-orcid":false,"given":"Paul J.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hami","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro De","family":"Los Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Colbourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.L.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Haerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Tunbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109262_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41371-020-0303-y","article-title":"The association of antihypertensive use and depressive symptoms in large older population with hypertension living in Australia and the United States: a cross-sectional study","volume":"34","author":"Agustini","year":"2020","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.neuropharm.2022.109262_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroscience.2019.09.041","article-title":"Calcium signaling in neurons and glial cells: role of Cav1 channels","volume":"421","author":"Alves","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109262_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13063-019-3175-0","article-title":"The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study","volume":"20","author":"Atkinson","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.neuropharm.2022.109262_bib4","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/brain\/awab443","article-title":"Analysing an allelic series of rare missense variants of CACNA1I in a Swedish schizophrenia cohort","volume":"145","author":"Baez-Nietro","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2022.109262_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00441-014-1806-z","article-title":"Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia","volume":"357","author":"Berridge","year":"2014","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2022.109262_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.06.001","article-title":"CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease","volume":"99","author":"Bhat","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/archgenpsychiatry.2010.96","article-title":"Genetic variation in CACNA1C affects brain circuitries related to mental illness","volume":"67","author":"Bigos","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.cell.2018.05.046","article-title":"Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes","volume":"173","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109262_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature22330","article-title":"Assembly of functionally integrated human forebrain spheroids","volume":"545","author":"Birey","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109262_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/JCP.0000000000001215","article-title":"Pharmacological implications of emerging schizophrenia genetics: can the bridge from \u2018genomics' to 'therapeutics' be defined and traversed?","volume":"40","author":"Birnbaum","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.116.08188","article-title":"Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders","volume":"68","author":"Boal","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2022.109262_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-3223(88)90287-9","article-title":"Calcium function in affective disorders and healthy controls","volume":"23","author":"Bowden","year":"1988","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib12","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM198212233072605","article-title":"Mechanism of action of calcium-channel-blocking agents","volume":"307","author":"Braunwald","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2022.109262_bib13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/nn.4411","article-title":"Translating genome-wide association findings into new therapeutics for psychiatry","volume":"19","author":"Breen","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib14","article-title":"A molecular approach to treating cognition in schizophrenia by calcium channel blockade: an open-label pilot study of the calcium-channel antagonist isradipine","volume":"21","author":"Burdick","year":"2020","journal-title":"Schizophr Res Cogn"},{"key":"10.1016\/j.neuropharm.2022.109262_bib15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jad.2019.08.075","article-title":"Distinct effects of antihypertensives on depression in the real-world setting: a retrospective cohort study","volume":"259","author":"Cao","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109262_bib16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ajmg.b.31122","article-title":"L-type calcium channels and psychiatric disorders: a brief review","volume":"153B","author":"Casamassima","year":"2010","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.neuropharm.2022.109262_bib17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/mp.2016.86","article-title":"A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development","volume":"21","author":"Cipriani","year":"2016","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41380-019-0583-1","article-title":"Long-read sequencing reveals the complex splicing profile of the psychiatric risk gene CACNA1C in human brain","volume":"25","author":"Clark","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biopsych.2021.03.009","article-title":"Developmental profile of psychiatric risk associated with voltage-gated cation channel activity","volume":"90","author":"Clifton","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01615-6","article-title":"Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders","author":"Colbourne","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41398-021-01444-1","article-title":"Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes","volume":"11","author":"Colbourne","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109262_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S003329170000619X","article-title":"Calcium metabolism and mental disorder","volume":"7","author":"Crammer","year":"1977","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109262_bib23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(12)62129-1","article-title":"Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2022.109262_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.biopsych.2021.04.008","article-title":"Induced pluripotent stem cells in psychiatry: an overview and critical perspective","volume":"90","author":"De Los Angeles","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/mp.2017.133","article-title":"Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood","volume":"23","author":"Dedic","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17425255.2019.1558206","article-title":"Applications of calcium channel blockers in psychiatry: pharmacokinetic and pharmacodynamic aspects of treatment of bipolar disorder","volume":"15","author":"Dubovsky","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib28","first-page":"781","article-title":"Intracellular calcium ions in affective disorders: a review and an hypothesis","volume":"18","author":"Dubovsky","year":"1983","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.209","article-title":"Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder","volume":"40","author":"Ferreira","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109262_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat8127","article-title":"Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder","volume":"362","author":"Gandal","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109262_bib31","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","article-title":"The novel anticonvulsant drug, gabapentin (Neurontin) binds to the alpha2\u03b4 subunit of a calcium channel","volume":"271","author":"Gee","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109262_bib32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/mp.2013.107","article-title":"A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain","volume":"19","author":"Gershon","year":"2014","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib33","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1073\/pnas.80.16.5122","article-title":"Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists","volume":"80","author":"Gould","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109262_bib34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.biopsych.2021.10.018","article-title":"Schizophrenia genomics: convergence on synaptic development, adult synaptic plasticity, or both?","volume":"91","author":"Hall","year":"2022","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib35","article-title":"Brain-enriched CACNA1C isoforms as novel, selective targets for psychiatric indications","author":"Hall","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109262_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13059-021-02542-5","article-title":"Roadblock: improved annotations do not necessarily translate into new functional insights","volume":"22","author":"Hall","year":"2021","journal-title":"Genome Biol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881114553647","article-title":"Recent genetic findings in schizophrenia and their therapeutic relevance","volume":"29","author":"Harrison","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib38","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/0269881120936501","article-title":"Rates of delirium associated with calcium channel blockers compared to diuretics, renin-angiotensin system agents and beta-blockers: an electronic health records network study","volume":"34","author":"Harrison","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1192\/bjp.2019.157","article-title":"Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal","volume":"216","author":"Harrison","year":"2020","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109262_bib40","first-page":"1","article-title":"Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes","author":"Harrison","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109262_bib41","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1038\/s41380-019-0622-y","article-title":"Cellular calcium in bipolar disorder: systematic review and meta-analysis","volume":"26","author":"Harrison","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104763","article-title":"New drug targets in psychiatry: neurobiological considerations in the genomics era","volume":"139","author":"Harrison","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109262_bib43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamapsychiatry.2018.3907","article-title":"Association of hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-Type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness","volume":"76","author":"Hayes","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pneurobio.2015.09.002","article-title":"Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders","volume":"134","author":"Heyes","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/070674379904400702","article-title":"Calcium channel blockers in psychiatric disorders: a review of the literature","volume":"44","author":"Hollister","year":"1999","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","article-title":"Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale","volume":"27","author":"Hong","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/genes8120344","article-title":"Alternative splicing of L-type CaV1.2 calcium channels: implications in cardiovascular diseases","volume":"8","author":"Hu","year":"2017","journal-title":"Genes"},{"key":"10.1016\/j.neuropharm.2022.109262_bib48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41593-020-0604-z","article-title":"Profiling gene expression in the human dentate gyrus granule cell layer reveals insights into schizophrenia and its genetic risk","volume":"23","author":"Jaffe","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib49","first-page":"37","article-title":"CSF calcium: clinical correlates in affective illness and schizophrenia","volume":"14","author":"Jimerson","year":"1979","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib50","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s13311-017-0532-0","article-title":"From gene to behavior: L-Type calcium channel mechanisms underlying neuropsychiatric symptoms","volume":"14","author":"Kabir","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.109262_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/acps.12957","article-title":"New drug candidates for depression - a nationwide population-based study","volume":"139","author":"Kessing","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2022.109262_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.biopsych.2010.10.032","article-title":"Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains","volume":"69","author":"Kleinman","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib53","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/molecules27041312","article-title":"Small molecules as modulators of voltage-gated calcium channels in neurological disorders: state of the art and perspectives","volume":"27","author":"Lanzetti","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2022.109262_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biopsych.2020.09.026","article-title":"Pleiotropy and cross-disorder genetics among psychiatric disorders","volume":"89","author":"Lee","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib55","first-page":"E4288","article-title":"Exclusion of alternative exon 33 of CaV1.2 calcium channels is proarrythmogenic","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109262_bib56","doi-asserted-by":"crossref","first-page":"35133","DOI":"10.1074\/jbc.M705478200","article-title":"A smooth muscle CaV1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine","volume":"282","author":"Liao","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109262_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1874467208666150507103215","article-title":"Calcium channel CaValpha(1) splice isoforms - tissue specificity and drug action","volume":"8","author":"Lipscombe","year":"2015","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib58","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bbamem.2012.09.018","article-title":"Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences","volume":"1828","author":"Lipscombe","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2022.109262_bib59","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sby096","article-title":"CACNA1C: association with psychiatric disorders, behaviour, and neurogenesis","volume":"44","author":"Moon","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2022.109262_bib60","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41588-021-00945-5","article-title":"An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci","volume":"53","author":"Mountjoy","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109262_bib61","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41588-021-00857-4","article-title":"Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology","volume":"53","author":"Mullins","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109262_bib62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.neuron.2018.03.017","article-title":"Calcium channels, synaptic plasticity, and neuropsychiatric disease","volume":"98","author":"Nanou","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109262_bib63","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1523\/JNEUROSCI.2946-16.2017","article-title":"Lower affinity of isradipine for L-Type Ca(2+) channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease","volume":"37","author":"Ortner","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00424-020-02418-w","article-title":"De novo CACNA1D Ca(2+) channelopathies: clinical phenotypes and molecular mechanisms","volume":"472","author":"Ortner","year":"2020","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.neuropharm.2022.109262_bib65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bdi.12143","article-title":"Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association","volume":"16","author":"Ostacher","year":"2014","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.neuropharm.2022.109262_bib66","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51037","article-title":"Aberrant calcium channel splicing drives defects in cortical differentiation in Timothy syndrome","volume":"8","author":"Panagiotakos","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2022.109262_bib67","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.biopsych.2014.11.020","article-title":"CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type calcium channels","volume":"77","author":"Pinggera","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev-physiol-031620-091043","article-title":"Voltage-gated calcium channels in non-excitable tissues","volume":"83","author":"Pitt","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109262_bib70","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41436-021-01232-8","article-title":"Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations","volume":"23","author":"Rodan","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.neuropharm.2022.109262_bib71","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1017\/S0033291719004094","article-title":"The relationship between antihypertensive medications and mood disorders: analysis of linked healthcare data for 1.8 million patients","volume":"51","author":"Shaw","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109262_bib72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109262_bib73","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/sj.mp.4002151","article-title":"Whole-genome association study of bipolar disorder","volume":"13","author":"Sklar","year":"2008","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib74","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.270.18.10540","article-title":"Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants","volume":"270","author":"Soldatov","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109262_bib75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajhg.2018.07.011","article-title":"Characterization of a human-specific tandem repeat associated with bipolar disorder and schizophrenia","volume":"103","author":"Song","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2022.109262_bib76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cell.2004.09.011","article-title":"Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism","volume":"119","author":"Splawski","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109262_bib77","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0165-6147(98)01171-7","article-title":"Structural basis of drug binding to L Ca2+ channels","volume":"19","author":"Striessnig","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib78","first-page":"15","volume":"vol. 3","author":"Striessnig","year":"2014"},{"key":"10.1016\/j.neuropharm.2022.109262_bib79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ceca.2006.08.002","article-title":"Signature combinatorial splicing profiles of rat cardiac- and smooth-muscle Cav1.2 channels with distinct biophysical properties","volume":"41","author":"Tang","year":"2007","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2022.109262_bib80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature19102","article-title":"Structural basis for inhibition of a voltage-gated Ca(2+) channel by Ca(2+) antagonist drugs","volume":"537","author":"Tang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109262_bib81","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamapsychiatry.2014.1079","article-title":"Expression of ZNF804A in human brain and alterations in schizophrenia, bipolar disorder, and major depressive disorder: a novel transcript fetally regulated by the psychosis risk variant rs1344706","volume":"71","author":"Tao","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib82","doi-asserted-by":"crossref","first-page":"17024","DOI":"10.1073\/pnas.0606539103","article-title":"Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel alpha1C subunit","volume":"103","author":"Tiwari","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109262_bib83","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109262_bib84","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JCP.0000000000001274","article-title":"Adjunctive raloxifene and isradipine improve cognitive functioning in patients with schizophrenia: a pilot study","volume":"40","author":"Vahdani","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01542-6","article-title":"Predicting causal genes from psychiatric genome-wide association studies using high-level etiological knowledge","volume":"27","author":"Wainberg","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib86","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/mol.118.112441","article-title":"Molecular determinants of the differential modulation of Cav1.2 and Cav1.3 by nifedipine and FPL 64176","volume":"94","author":"Wang","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109262_bib87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41593-019-0382-7","article-title":"A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data","volume":"22","author":"Wang","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41398-022-01851-y","article-title":"Identification of ultra-rare disruptive variants in voltage-gated calcium channel-encoding genes in Japanese samples of schizophrenia and autism spectrum disorder","volume":"12","author":"Wang","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109262_bib89","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1523\/JNEUROSCI.4673-09.2010","article-title":"L-type voltage-gated Ca2+ channels: a single molecular switch for long-term potentiation\/long-term depression-like plasticity and activity-dependent metaplasticity in humans","volume":"30","author":"Wankerl","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad2395","article-title":"Structure of the voltage-gated calcium channel Cav1.1 complex","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109262_bib91","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/mp.2016.241","article-title":"Molecular mechanisms underlying noncoding risk variations in psychiatric genetic studies","volume":"22","author":"Xiao","year":"2017","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib92","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1523\/JNEUROSCI.21-16-05944.2001","article-title":"Neuronal CaV1.3\u03b11 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inactivated by dihydropyridines","volume":"21","author":"Xu","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109262_bib93","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mp.2014.143","article-title":"Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons","volume":"20","author":"Yoshimizu","year":"2015","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib94","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2015.5","article-title":"Targeting voltage-gated calcium channels in neurological and psychiatric diseases","volume":"15","author":"Zamponi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2022.109262_bib95","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109262_bib96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41380-021-01037-w","article-title":"An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data","volume":"27","author":"Zhang","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109262_bib97","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0014-5793(98)00425-6","article-title":"Ca2+ channel sensitivity towards the blocker isradipine is affected by alternative splicing of the human alpha1C subunit gene","volume":"427","author":"Zuhlke","year":"1998","journal-title":"FEBS Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:21:47Z","timestamp":1758439307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":97,"alternative-id":["S0028390822003215"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109262","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109262"}}